0 Yorumlar
0 hisse senetleri
2K Views
0 önizleme
Site içinde arama yapın
Yeni insanlarla keşfedin, yeni bağlantılar oluşturmak ve yeni arkadaşlar edinmek
-
Please log in to like, share and comment!
-
Chronic Kidney Disease - Mineral Bone Disorders (CKD-MBD) Treatment Market Dynamics: Key Drivers and RestraintsFuture of Executive Summary Chronic Kidney Disease - Mineral Bone Disorders (CKD-MBD) Treatment Market: Size and Share Dynamics CAGR Value The global chronic kidney disease - mineral bone disorders (CKD-MBD) treatment market size was valued at USD 2.39 billion in 2024 and is expected to reach USD 4.80 billion by 2032, at a CAGR of 9.09% during the forecast...0 Yorumlar 0 hisse senetleri 533 Views 0 önizleme
-
Chronic Kidney Disease - Mineral Bone Disorders (CKD-MBD) Treatment Market Overview: Key Drivers and ChallengesRegional Overview of Executive Summary Chronic Kidney Disease - Mineral Bone Disorders (CKD-MBD) Treatment Market by Size and Share CAGR Value The global chronic kidney disease - mineral bone disorders (CKD-MBD) treatment market size was valued at USD 2.39 billion in 2024 and is expected to reach USD 4.80 billion by 2032, at a CAGR of 9.09% during the...0 Yorumlar 0 hisse senetleri 419 Views 0 önizleme
-
Chronic Kidney Disease - Mineral Bone Disorders (CKD-MBD) Treatment Market: Size, Share, and Future GrowthChronic Kidney Disease - Mineral Bone Disorders (CKD-MBD) Treatment Market Summary: According to the latest report published by Data Bridge Market Research, the Chronic Kidney Disease - Mineral Bone Disorders (CKD-MBD) Treatment Market CAGR Value The global chronic kidney disease - mineral bone disorders (CKD-MBD) treatment market size was valued at USD 2.39 billion in...0 Yorumlar 0 hisse senetleri 255 Views 0 önizleme
-
Is the Global EPO Drugs Market Expanding With Rising Chronic Kidney Disease and Anemia Cases?Executive Summary Erythropoietin (EPO) Drugs Market Size and Share Forecast The global erythropoietin (EPO) drugs market size was valued at USD 9.12 billion in 2024 and is expected to reach USD 22.60 billion by 2032, at a CAGR of 12.00% during the forecast period The Erythropoietin (EPO) Drugs report also makes available CAGR value fluctuation...0 Yorumlar 0 hisse senetleri 1K Views 0 önizleme